Topic
Mass screening
About: Mass screening is a research topic. Over the lifetime, 34508 publications have been published within this topic receiving 1365148 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: An overview of the fundamental points and principles that should support any quality-assured screening programme and key performance indicators are presented here in a summary document of the second guidelines edition in order to make these principles and standards known to a wider scientific community.
672 citations
••
TL;DR: This study provides a fall-risk screening test based on four easily measurable predictors that can be used for fall- risk stratification in community-dwelling elderly.
671 citations
••
TL;DR: The revised Primary Care PTSD screen (PC-PTSD) was revised to reflect the new Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD and demonstrated strong preliminary results for diagnostic accuracy, and was broadly acceptable to patients.
Abstract: BACKGROUND
Posttraumatic Stress Disorder (PTSD) is associated with increased health care utilization, medical morbidity, and tobacco and alcohol use. Consequently, screening for PTSD has become increasingly common in primary care clinics, especially in Veteran healthcare settings where trauma exposure among patients is common.
665 citations
••
TL;DR: Examination of the association of olfactory dysfunction with future development of PD in Honolulu‐Asia Aging Study cohort members finds that it can predate the onset of clinical PD in a community‐based population.
Abstract: Objective
Although olfactory dysfunction is commonly associated with Parkinson's disease (PD), it is not known whether such dysfunction can predate the onset of clinical PD in a community-based population. This study examines the association of olfactory dysfunction with future development of PD in Honolulu-Asia Aging Study cohort members
Methods
Olfaction was assessed from 1991 to 1996 in 2,267 men in the Honolulu-Asia Aging Study aged 71 to 95 years who were free of clinical PD and dementia at the time of olfaction testing. Participants were followed for up to 8 years for incident PD
Results
In the course of follow-up, 35 men were diagnosed with PD (24.6/10,000 person-years). The average age at the time of diagnosis was 82.9 ± 3.8 (range, 76–93) years, and the average time to a diagnosis was 4.0 ± 1.9 (range, 1–8) years. During the first 4 years of follow-up, age-adjusted incidence of PD declined from 54.5/10,000 person-years in the lowest quartile of odor identification to 26.6, 8.2, and 8.4/10,000 person-years in the second, third, and fourth quartiles, respectively (p < 0.001 for trend). After adjustment for age and other potential confounders, the odds ratios for PD in the lowest quartile was 5.2 (95% confidence interval, 1.5–25.6) compared with the top two quartiles. This relation was not evident beyond 4 years of follow-up
Interpretation
Impaired olfaction can predate clinical PD in men by at least 4 years and may be a useful screening tool to detect those at high risk for development of PD in later life. Ann Neurol 2007
662 citations
••
TL;DR: The association of serum cholesterol with specific causes of death varies in direction, strength, gradation, and persistence, and further research on the determinants of low serum cholesterol level in populations and long-term follow-up of participants in clinical trials is necessary.
Abstract: Background.— With increased efforts to lower serum cholesterol levels, it is important to quantify associations between serum cholesterol level and causes of death other than coronary heart disease, for which an etiologic relationship has been established. Methods.— For an average of 12 years, 350 977 men aged 35 to 57 years who had been screened for the Multiple Risk Factor Intervention Trial were followed up following a single standardized measurement of serum cholesterol level and other coronary heart disease risk factors; 21 499 deaths were identified. Results.— A strong, positive, graded relationship was evident between serum cholesterol level measured at initial screening and death from coronary heart disease. This relationship persisted over the 12-year follow-up period. No association was noted between serum cholesterol level and stroke. The absence of an association overall was due to different relationships of serum cholesterol level with intracranial hemorrhage and nonhemorrhagic stroke. For the latter, a positive, graded association with serum cholesterol level was evident. For intracranial hemorrhage, cholesterol levels less than 4.14 mmol/L ( Conclusions.— The association of serum cholesterol with specific causes of death varies in direction, strength, gradation, and persistence. Further research on the determinants of low serum cholesterol level in populations and long-term follow-up of participants in clinical trials are necessary to assess whether inverse associations with noncardiovascular disease causes of death are consequences of noncardiovascular disease, whether serum cholesterol level and noncardiovascular disease are both consequences of other factors, or whether these associations are causal. ( Arch Intern Med . 1992;152:1490-1500)
662 citations